Henlius 2022 Annual Results Presentation - Biotech

Henlius reported 2022 revenue of 3.21 billion RMB with 91.1% year-over-year growth, driven by successful product launches and biosimilar out-licensing deals. The company expanded its pipeline with 50+ programs, achieved 48KL commercial manufacturing capacity, and established clinical operations in the US and Australia. Key achievements include FDA/EMA endorsement of ASTRUM-005 and global partnerships including co-development with Nobel Laureate-founded Palleon.